JP2021519753A - 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 - Google Patents

眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 Download PDF

Info

Publication number
JP2021519753A
JP2021519753A JP2020552191A JP2020552191A JP2021519753A JP 2021519753 A JP2021519753 A JP 2021519753A JP 2020552191 A JP2020552191 A JP 2020552191A JP 2020552191 A JP2020552191 A JP 2020552191A JP 2021519753 A JP2021519753 A JP 2021519753A
Authority
JP
Japan
Prior art keywords
amino
retinal
carboxylic acid
pharmaceutically acceptable
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519753A5 (https=
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2021519753A publication Critical patent/JP2021519753A/ja
Publication of JP2021519753A5 publication Critical patent/JP2021519753A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020552191A 2018-03-29 2019-03-29 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 Pending JP2021519753A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650004P 2018-03-29 2018-03-29
US62/650,004 2018-03-29
PCT/US2019/024726 WO2019191525A1 (en) 2018-03-29 2019-03-29 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders

Publications (2)

Publication Number Publication Date
JP2021519753A true JP2021519753A (ja) 2021-08-12
JP2021519753A5 JP2021519753A5 (https=) 2022-04-01

Family

ID=68056529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552191A Pending JP2021519753A (ja) 2018-03-29 2019-03-29 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用

Country Status (10)

Country Link
US (1) US20190298674A1 (https=)
EP (1) EP3758693A4 (https=)
JP (1) JP2021519753A (https=)
KR (1) KR20210009306A (https=)
CN (1) CN112218628A (https=)
AU (1) AU2019243586A1 (https=)
CA (1) CA3095468A1 (https=)
IL (1) IL277599A (https=)
MX (1) MX2020010302A (https=)
WO (1) WO2019191525A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202021080A2 (tr) * 2020-12-21 2022-07-21 Marmara Ueniversitesi Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇
EP4482478A4 (en) * 2022-02-27 2026-03-04 Univ Northwestern (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS
KR20250034134A (ko) * 2022-07-06 2025-03-10 오비드 테라퓨틱스 인크. 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용
US20240285565A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
JP2026506097A (ja) * 2023-02-17 2026-02-20 オービッド・セラピューティクス・インコーポレイテッド 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US20140336256A1 (en) * 2012-01-27 2014-11-13 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US20170101364A1 (en) * 2015-10-09 2017-04-13 Richard B. Silverman (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and Related Compounds as GABA Aminotransferase Inactivators for the Treatment of Epilepsy, Addiction and Hepatocellular Carcinoma
JP2017533964A (ja) * 2014-11-07 2017-11-16 ノースウエスタン ユニバーシティ 肝細胞癌を治療する為のｇａｂａ類似体を用いたオルニチンアミノ基転移酵素の阻害方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US10632088B2 (en) * 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
EP4692048A3 (en) * 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329
KR20250167147A (ko) * 2018-02-08 2025-11-28 오비드 테라퓨틱스 인크. 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도
MX2020012691A (es) * 2018-05-25 2021-02-15 Univ Northwestern Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US20140336256A1 (en) * 2012-01-27 2014-11-13 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
JP2017533964A (ja) * 2014-11-07 2017-11-16 ノースウエスタン ユニバーシティ 肝細胞癌を治療する為のｇａｂａ類似体を用いたオルニチンアミノ基転移酵素の阻害方法
US20170101364A1 (en) * 2015-10-09 2017-04-13 Richard B. Silverman (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and Related Compounds as GABA Aminotransferase Inactivators for the Treatment of Epilepsy, Addiction and Hepatocellular Carcinoma
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 140, JPN6023002811, 30 January 2018 (2018-01-30), pages 2151 - 2164, ISSN: 0004977704 *
NEUROSCIENCE LETTERS, vol. 588, JPN6023002810, 2015, pages 108 - 113, ISSN: 0004977705 *

Also Published As

Publication number Publication date
MX2020010302A (es) 2021-01-08
CA3095468A1 (en) 2019-10-03
CN112218628A (zh) 2021-01-12
IL277599A (en) 2020-11-30
AU2019243586A1 (en) 2020-10-15
EP3758693A1 (en) 2021-01-06
US20190298674A1 (en) 2019-10-03
EP3758693A4 (en) 2021-06-02
WO2019191525A1 (en) 2019-10-03
KR20210009306A (ko) 2021-01-26

Similar Documents

Publication Publication Date Title
JP2021519753A (ja) 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用
EP3681500B1 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
JP5878172B2 (ja) 炎症性眼疾患の治療／予防用化合物
CN114786480B (zh) 使用内皮素受体拮抗剂治疗眼部疾病
JP2019534870A (ja) 眼疾患の治療のための組成物ならびに使用および調製方法
JPH08502033A (ja) ＴＧＦ−βを用いる眼疾患の治療方法
US20250205346A1 (en) Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd
JP6768780B2 (ja) エンドセリン受容体の拮抗薬の局所用眼科製剤およびそれらの使用
MXPA05000773A (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad.
Shukla et al. Macular hole secondary to X-linked retinoschisis
US20210059969A1 (en) Alpha-aminoadipate for treatment of vision loss and restoring sight
Aşikgarip et al. Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration
JPH10167963A (ja) 低級アルカノイルｌ−カルニチンを含有する網膜症治療用製剤
KR102293398B1 (ko) Si를 이용한 망막 변성 개 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
Fung et al. Patient Management in Clinical Practice
JP2014510115A (ja) 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤
US10780070B2 (en) Alpha-aminoadipate for treatment of vision loss and restoring sight
WO2023192691A2 (en) Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
JP2003501461A (ja) 神経保護性及び網膜保護性眼科薬
JP2024516829A (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
RU2271208C2 (ru) Способ лечения сенильной макулярной дегенерации с неоваскулярным синдромом
Monaco et al. Congenital iris ectropion associated with juvenile glaucoma
WO2025128712A1 (en) Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs
Arikan et al. Bilateral combined cilioretinal artery and central retinal vein occlusion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829